Cutaneous T cell lymphomas are characterized by an accumulation of malignant clonal lymphocytes in the skin and occasionally in the blood. We compared gene transcription pro®les from cultured clonal lymphocytes with autologous healthy blood lymphocytes by microarray hybridization. Cutaneous T cell lymphoma derived cells transcribed high amounts of an interferon inhibiting cytokine factor. The presence of an interferon inhibiting cytokine factor was con®rmed in 12 skin biopsies of mycosis fungoides and Se Âzary syndrome derived blood lymphocytes by reverse transcriptase±polymerase chain reaction. The presence of interferon inhibiting cytokine factor mRNA in Se Âzary syndrome derived lymphocytes was associated with a lack of HLA class II upregulation after stimulation with interferon-a and interferon-g. This was not due to a loss of the interferon signaling cascade as the presence of interferon-signaling components was con®rmed by reverse transcriptase±polymerase chain reaction on the transcriptional level. The elevated constitutive interferon inhibiting cytokine factor expression observed in cutaneous T cell lymphoma derived cells was insensitive to interferon-g stimulation, but was enhanced in normal peripheral blood mononuclear cells. We suggest that interferon inhibiting cytokine factor contributes to the lack of HLA class II upregulation in lymphoma cells. Interferon inhibiting cytokine factor may participate in providing a microenvironment at the tumor site insensitive to interferon-g stimulation and thus prevents an ef®cient local immune response. Key words: immune escape/microarray hybridization/SeÂzary syndrome. J Invest Dermatol 116: 874±879, 2001 C utaneous T cell lymphomas (CTCL) comprise a heterogeneous group of neoplasms characterized by an accumulation of malignant T lymphocytes in skin and occasionally, as in Se Âzary syndrome (SS), in skin and blood. Based on clinical, histologic, and immunologic features, we suppose that the tumor cells in SS and probably also in mycosis fungoides (MF) are well differentiated skin homing (Kamarashev et al, 1998) T helper 2 lymphocytes (Sterry and Mielke, 1989; Vowels et al, 1994; Asadullah et al, 1996; Dummer et al, 1996) , often lacking CD7 expression (Wood et al, 1993) with a low proliferation rate, but an increased expression of anti-apoptotic proteins, such as bcl-2 in early stages and enhanced proliferation in advanced stages Dummer et al, 2000) . Recently, it was demonstrated that clonal T cells derived from SS fail to respond to interferon (IFN) -a and IFN-g (Dummer et al, 1998 (Dummer et al, , 2001 and to interleukin-12 (Showe et al, 1999) . As tumor-speci®c molecular alteration might present targets for future therapeutic strategies Dummer et al, 2001) , we aim to identify genes preferentially expressed in the malignant T cells.
The microarray technique is a powerful tool to identify transcriptional differences between benign and malignant cells for large numbers of genes (Sikic, 1999; Lockhart and Winzeler, 2000) . We perform microarray hybridization on isolated CTCL-derived cells and compared the resulting pro®le with autologous healthy peripheral blood derived T helper cells, otherwise displaying widespread similarities. The IFN-g inhibiting cytokine (IK) ®rst described by Krief et al (1994) appeared overexpressed in CTCLderived cells. This factor IK was shown to inhibit IFN-g induced expression of HLA class II antigen.
MATERIALS AND METHODS
Patients MF and SS was diagnosed using standard clinical criteria (Burg et al, 1995) (erythroderma, lymphadenopathy), histologic (subepidermal lymphoid in®ltrate showing strong epidermotropism and expressing a T helper cell phenotype), and for SS hematologic criteria (more than 1000 SS cells per ml), and an elevated CD4/CD8 ratio (van Willemze et al, 1983; Heald et al, 1994) . All patients were seronegative for human T cell lymphocytic virus I antibodies by enzyme-linked immunosorbent assay. Patients did not receive any systemic therapy in the last 2 wk before blood was taken; however, topical steroids had to be applied to control itching. The biopsy site was spared at least 5 d before tumor sampling. For detailed patient information refer to Puri®cation and culture of malignant clones and normal CD4 + cells All human material was obtained with the patient's informed consent. CD4 + cells were separated by an immunomagnetic procedure using paramagnetic polystyrene beads (Dynal, Lake Success, NY) and a magnetic separation device (Dynal). An anti-human CD4-speci®c murine IgM antibody (Dako, Glostrup, Denmark) was conjugated to Dynabeads M-450 (Dynal) by overnight incubation at pH 9.5, washed twice in phosphate-buffered saline containing 10% fetal bovine serum and incubated under constant slow agitation with peripheral blood mononuclear cells (PBMC) generated by Ficoll gradient enrichment from the patient's blood at 4°C. Puri®ed CD4 + T cells were stimulated by exposure to 10mg per ml PHA (Gibco, Grand Island, NY) and harvested on day 3. Lymphocytic cells from a diagnostic MF tumor sample were cultured for 8 wk in RPMI 1640 medium (500 ml), supplemented with 100 ml fetal bovine serum (» 20%), 10 ml fungizone/streptomycin, 10 ml glutamine, 5 ml sodium pyruvate (all Gibco BRL), 100 ml human epidermal growth factor (= 1 mg), 200 ml interleukin-2 (10 6 u per ml), 2 ml interleukin-4 (50,000 u per ml), 2 ml granulocyte-monocyte colony-stimulating factor (80,000 u per ml), and 400 ml basic ®broblast growth factor (250,000 u per ml) (all Becton Dickinson, San Jose, CA). Clonality of the morphologically homogenous tumor cell population was determined by PCR/denaturing gradient gel electrophoresis as described previously and compared with original cryopreserved biopsy material (Wood et al, 1994) . Autologous peripheral CD4 + T cells were cultured for 3 d under identical conditions in order to normalize for tissue culture artifacts.
Microarray hybridization Four different pairs of samples have been analyzed. Total mRNA (3 mg) obtained from CTCL patient's derived clonal T cell cultures and autologous normal CD4 + PBMC, respectively, was reverse transcribed using the cDNA Synthesis (CDC) Primer Mix including (a-32 P)deoxyadenosine triphosphate into radioactively labeled cDNA (Atlas TM Pure Total Labeling System, Clontech, Palo Alto, CA). The probes were then hybridized to separate Atlas Arrays (``Human Cancer'' comprising 588 different tumor-related genes) following the manufacturer's instructions (Atlas TM cDNA Expression Array, Clontech) and expression pro®les visualized by phosphoimaging scans.
Flow cytometry Surface receptor status of PBMC and CTCL cells was analyzed using anti-HLA-ABC monoclonal antibody (MoAb) W6.32 (Dako Diagnostics, Zug, Switzerland), anti-HLA-DR MoAb L243 (BD/Pharmingen, Heidelberg, Germany), anti-IFN-a receptor 1 MoAb (kindly provided by Dr. Novick), anti-IFNAR2 MoAb (Transduction Laboratories, Maechler AG, Basel, Switzerland), anti-IFN-g receptor (anti-IFNGR) 1 MoAb A6-C5 (kindly provided by Dr Hemmi, Institute for Molecular Biology, Zu Èrich), anti-IFNGR2 MoAb Hub159 (Genzyme Diagnostics, Kings Hill, U.K.). As isotype control mouse IgG1, IgG2a antibodies, and hamster IgG antibodies (all BD/ Pharmingen) have been used, respectively. As secondary reagents uorescence conjugated rabbit anti-mouse (RAM) polyclonal antibodies (Dako), biotin-labeled goat anti-hamster polyclonal MoAb (CALTAG, Burlingame, CA) and¯uorescence conjugated streptavidin (Dako) have been used.
Reverse transcriptase±polymerase chain reaction (RT±PCR) For IK, mRNA detection total mRNA was extracted from CTCL cell cultures, tissue samples and PBMC culture using RNAeasy Mini Kit (Qiagen AG, Basel, Switzerland), following the manufacturer's instructions ( Table I ). In addition, from two SS patients (PL and XB) and normal donor blood, PBMC were isolated with Ficoll-Paque (Amersham, Uppsala, Sweden), pelleted, and then resuspended in buffer A (10 mM HEPES, 10 mM KCl, 1 mM ethylenediamine tetraacetic acid, 1 mM ethyleneglycol-bis-(b-aminoethylether)-N,N,N¢,N¢tetraacetic acid) and lyzed by vortexing with the addition of 1/16 vol. of 10% nonidet P40. The supernatant was added to an equal volume of buffer B (7 M urea, 1% sodium dodecyl sulfate, 0.35 M NaCl). After one phenol/chloroform/ethanol extraction the RNA was dissolved in RNAse-free water. From all isolated RNA samples mounts between 2 and 4 mg RNA were used to synthesize cDNA (M-MuLV Reverse Transcriptase from New England Biolabs, Beverly, MA). PCR was performed with the incubation buffer supplied with the Taq DNA polymerase (Boehringer Mannheim, Mannheim, D), with PCR digoxigenin labeling nucleotide mix (Boehringer Mannheim), and with 2.0 mM oligonucleotide primers. The cDNA probes were ®rst ampli®ed with primers for b-actin to test the quality and quantity of the cDNA. Only satisfactory cDNA was then subjected to PCR with primers for Clonal dominance of T cell receptor Vb chain of all CD4 + cells VOL. 116, NO. 6 JUNE 2001 IFNAR1 and 2, IFNGR1 and 2, JAK-1 and STAT-1, respectively. Table II shows the primer sequences. Intron-spanning primers were selected using the OLIGO Primer Analysis Software program version 4.0 (National Biosciences, Cascade, CO). Primer sequences were sent to GenBank to exclude cross-binding to other published sequences (Altschul et al, 1990) . PCR was performed with Perkin Elmer 9600 GenAmp cyclers (Wellesley, MA). DNA-fragments were ampli®ed with 30 cycles and an annealing temperature of 55°C. An aliquot of PCR product was electrophoresed on a 1.6% agarose gel and visualized by ethidium bromide staining. In all PCR reactions positive controls from various cell lines and water as negative control were included. MgCl 2 concentrations, 2 ml cDNA and water to a ®nal volume of 20 ml. Ampli®cation occured as a three-step cycling procedure: denaturation 95°C, 15 s; annealing 66°C, 10 s; and elongation 72°C, 18 s for 40 cycles. External standards for the b-actin quantitation consisted of four serial 1 : 10 dilutions (5.4 Q 10 4 to 5.4 Q 10 7 copies per reaction) of a pCR2.1 b-actin plasmid. External standards were run concomitantly with patients' samples under identical conditions. The¯uorescence signal was plotted against the cycle number for all samples and external standards. The Fit Points method option was used in the course of analyzing quantitation data, allowing the de®nition of a noise band and subsequent background¯uorescence subtraction, and resulting in the display of only log-linear and plateau ampli®cation phases. A standard curve was then generated for each run, plotting the crossing point against the log-concentration of the standards. Normalization of estimated IK amounts was achieved by calculating the ratios between IK and b-actin, in order to compensate the variations in quantity and quality of starting mRNA. Ten microliters of each ampli®cation product were checked by electrophoresis on a 2% agarose gel stained with ethidium bromide. The estimated size of the ampli®ed fragments matched the calculated size. Product identity was in parallel checked by melting curve analysis, which is another application in the LightCycler analysis program.
Real-time quantitative PCR

RESULTS
Overexpression of IK mRNA in cutaneous lymphoma cells detected in microarray hybridization Total RNA of patient's skin derived CTCL cell cultures was isolated and subjected for hybridization with 588 tumor-related genes on a microarray. An overlay subtracts the hybridization signal obtained with CTCL cells, from the signal obtained with autologous healthy PBMC (SW, TR) or with allogenic CD4 + cells (VM, RM). A consistent overexpression in all four microarray tested patient samples was found for the IK mRNA. Figure 1 demonstrates the microarray hybridization results for patient SW. Subsequent reverse transcriptase±PCR analysis with extended patient numbers revealed the presence of the IK mRNA in 11 skin biopsies, blood samples or cell cultures of CTCL patients and the lymphoma cell line Jurkat ( Table I, Fig 1 insert) . In contrast to that, RNA isolated from healthy donor's PBMC showed no band (ZK). The same was true for RNA isolated from CD7 + cells of the SS patient KH (Fig 1 insert; KH 1 ) .
Unresponsiveness of patient's PBMC to IFN stimulation As IK was found to be overexpressed in CTCL cells we asked, whether IFN are still effective on CTCL cells and if they can stimulate the HLA class II expression in these cells. A clear upregulation of HLA class II expression with either IFN-a or IFNg was only seen in gated lymphocytes from healthy controls but not in gated lymphocytes derived from two SS patients with high clonality (XB, PL), although a basic level of HLA class II protein expression was detected (Fig 2) . Jurkat cells did not express HLA class II at all.
Differential expression of IFNR chains on patients' PBMC and healthy donor PBMC The patients XB and PL were tested for expression of IFNR chains and associated proteins by IFNAR1  TTG CTC TCC CGT TTG TCA TTT A  GAC CTC AGG CTC CCA GTG TAA C  395  IFNAR2  CCA CCT CTA CAG AAT CCC AGT T  GGA GAA CAC TTG CAG ACG ATA A  591  IFNGR1  TTG GAT TCC AGT TGT TGC TGC TT  TGT CCA GGA AAA TCA GAC TTC AA  775  IFNGR2  CCT CCA CTG AGC TTC AGC AAG TC  CAA AAG GGA ATA CTG GTC TCT GG  394  STAT-1  CAA GGT GGC AGG ATG TCT CAG TG  TGG TCT CGT GTT CTC TGT TCT GC  565  JAK-1  GGA CCC CAC ACA TTT TGA GAA GC  TGC AGA GTG ACT CCA AAA GAC CA  645  IK  GCA GCT GGG AGA TTT CTT TG  GGG CAA AGC TTC TTT GTT ¯uorescence-activated cell sorter (FACS) analysis and reverse transcriptase±PCR in order to evaluate a functional signal transduction pathway. There were prominent differences in basal levels of protein expression and, however, after IFN stimulation no consistent regulation of IFNR chains expression was detectable ( Table III) . The same was true for healthy control PBMC and Jurkat cells. Patient XB revealed strong expression of IFNGR1 and 2 chains, whereas patient PL expressed high amounts of IFNGR1, which disappeared after stimulation and almost no expression of IFNGR2. Reverse transcriptase±PCR analysis revealed the presence of mRNA for all tested IFN signaling components in both patients. The results for PBMC and Jurkat cells, however, appeared heterogeneous.
IFN-g upregulated IK transcription in healthy donor PBMC but not in CTCL patient derived CD4 + cells In order to evaluate the functional properties of IK we incubated sorted patient derived CD4 + cells (SM, CT, ZA, WR) and outgrown clonal lymphoma cells (BB) with IFN-g and then isolated RNA for reverse transcriptase±PCR analysis. With real-time PCR we have been able to measure IK mRNA levels and b-actin mRNA levels as external standards. Figure 3 shows the ratios of IK mRNA compared with b-actin mRNA. Four of ®ve CTCL patients showed almost no change in IK mRNA transcription after IFN-g stimulation. One patient, however, responded with an increase of IK mRNA. It is noteworthy that this particular patient showed an extremely low level of IK mRNA in unstimulated CD4 + cells. In comparison with that, we found an increase of IK mRNA levels after IFN-g stimulation in CD4 + cells from healthy donors as well.
DISCUSSION
The study of differential gene expression patterns in tumor cells vs their benign autologous counterpart by array technology opens new dimensions in illuminating the molecular biology of neoplasms. Expression levels of large amounts of genes can be compared simultaneously and may help to identify characteristic pro®les for tumor cells (Bittner et al, 2000) . First approaches in diffuse large B cell lymphomas demonstrate a correlation of tumor-speci®c properties and prognosis (Alizadeh et al, 2000) . We cultured tumor cells from four patients with MF and compared their gene expression pro®le with autologous or allogenic CD4 + cells, respectively. In repeated experiments CTCL biopsies and outgrown clonal T cells derived from 12 MF and SS patients demonstrated consistent overexpression of factor IK (Figs 1 and 3) , an IFN-g inhibiting cytokine ®rst described by Freshly isolated PBMC from two SS patients containing a clonal T cell population of 73.8% (XB) and 81.3% (PL) of all CD4 + cells in the blood were cultured 70 h with or without 500 U per ml IFN-a, or IFN-g, respectively. Then, cells were washed and stained with¯uorescence conjugated antibodies against HLA class II. Stained cells were analyzed in a¯ow cytometer and gated on lymphocytes. Flow cytometric data are presented as average shift (ratio of mean uorescence of speci®c antibody vs appropriate isotype-matched control antibody). Jurkat cells showed no HLA class II expression at all (A). Additionally, (B) compares histograms of isotype controls (®lled gray curves) vs. speci®c antibody stainings (open black curves). Krief et al (1994) . This factor IK was shown to inhibit IFN-ginduced expression of HLA class II antigen. Moreover, IK is expressed in CD34 + hematopoietic progenitors, and its expression can be upregulated during growth factor-induced differentiation (Cao et al, 1997) . Studies, that were done in IK transfected Raji B cell lines led to a model in which IK inhibits the constitutive HLA class II expression through repression of the class II transactivator (CIITA) transcription. Differential expression of CIITA plays an important part for the stabilization and activity of the transcription complex. Several, yet unknown intermediate proteins may be involved between IK and CIITA promotors (Vedrenne et al, 1997) . As CIITA is hardly expressed in IK transfected Raji B cells, it appears that IK acts through a negative regulation of CIITA expression. That means IK inhibits both, the CIITA promoter III and IV of which the ®rst is responsible for a constitutive gene expression and the latter renders responsible for an IFN-g induced expression (Morris et al, 2000) .
In order to investigate, whether the overexpressed IK is functional we studied PBMC from advanced SS containing at least 75% clonal T cells as assessed by FACS (Dummer et al, 1996 (Dummer et al, , 2001 . In contrast to normal PBMC, SS derived PBMC failed to upregulate HLA class II expression upon IFN stimulation.
Stimulation with IFN-g does not in¯uence the IK levels in most of the CTCL cells; however, normal PBMC respond with an upregulation of IK mRNA transcription. This is especially interesting as these cells are sensitive to IFN-g and increase the HLA class II expression upon stimulation.
IFN-g binds to a speci®c ubiquitous cell surface receptor, consisting of two transmembrane proteins, namely IFNGR1 chain, IFNGR2 chain (Bach et al, 1996) . The signal transduces through a cascade of phosphorylations and then leads to the activation of CIITA, which in turn induces HLA class II expression (Steimle et al, 1994) and to some extend HLA class I expression as well (Martin et al, 1997) .
A natural role of IFN in tumor surveillance is demonstrated in mouse tumor models where treatment with antibodies directed against IFN leads to the stimulation of growth and proliferation of tumor cells. The IFNGR ±/± mouse model was used to address the question whether IFN-g plays a crucial part in promoting host surveillance that is capable of controlling the growth of primary tumors. After treatment with chemical carcinogens, IFN-g-resistant animals developed tumors more frequently than wild-type controls (Kaplan et al, 1998) . Bach et al (1995) used an in vitro developmental system showing that IFN-g stops the expression of the IFNGR2 chain, resulting in Th1 cells that are unresponsive to IFN-g. This receptor chain loss also occurred in IFN-g-treated Th2 cells (Bach et al, 1995) . Their data suggest that IFNGR2 loss is a speci®c response of CD4 + T cells to IFN-g treatment rather than a Th1 speci®c differentiation event. According to Bach et al (1995) , it is also possible that IFNGR2 overexpression is a sign of IFN-g depletion in SS blood. We found similar heterogeneous results in our FACS analysis (Table III) . Although we showed the presence of most IFNR chains in our patients, this does not prove a functional integrity of Figure 3 . IFN-g fails to enhance IK mRNA expression in CTCL derived lymphocytes as measured by real-time reverse transcriptase±PCR (LightCycler). From ®ve CTCL patients malignant cells have been isolated and stimulated for 24 h with IFN-g (500 U per ml). Then, RNA has been isolated and transcribed into cDNA. The quality and quantity of cDNA has been checked with primers speci®c for b-actin, followed by a PCR with primers speci®c for IK. Data are expressed as ratios of IK transcripts vs b-actin transcripts. Because of limited patient material only one experiment per sample could be performed. In case of healthy control PBMC the mean of three individual experiments including standard error of the mean (SEM) are presented. Each single control sample showed higher IK level after IFNg stimulation.
the IFN signaling pathway (Dummer et al, 2001) . Further analysis on mRNA levels revealed the presence of IFNR chain mRNA in both investigated patients.
According to Vedrenne et al (1997) the overexpression of the IK protein maintains CIITA expression under a threshold, inducing a latent state of HLA-DR transcription repression. They suggest that the IK/CIITA ratio represents a crucial controlling element for HLA class II membrane expression. We believe that the threshold for HLA class II expression can be easily overcome after IFN-g stimulation in normal cells, by producing suf®cient amounts of CIITA, which is then feedback regulated by rising IK levels. In malignant cells, however, frequently de®cient in IFN-signaling this regulatory loop is impaired, thus leading to constant high IK levels and inhibition of IFN-g induced HLA class II protein expression.
Based on our data, we speculate that the clonal T cells create a microenvironment where high levels of IK inhibit the bene®cial effects of IFN-g in the surrounding tissue. A constant overexpression of IK limits the CIITA activation and, therefore, the induction of HLA class II protein. We are aware of the fact that this regulatory pathway might be only one of many switches in a complex microenvironmental network. The characterization of factors involved in the control of HLA class II expression in healthy and malignant cells, however, will be important to understand the underlying molecular mechanisms. Successful immunointervention in MF and SS might aim to restore reduced HLA class II facilitating a better recognition by immunosurveillance (Martin et al, 1999) .
